Morgan Stanley Makes Positive Commnents on Momenta Pharmaceuticals (MNTA)
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
CONTRIBUTOR http://notablecalls.blogspot.com
Morgan Stanley is positive on Momenta Pharma (NASDAQ: MNTA) saying that after attending the ongoing '618 patent litigation, they believe there is a high likelihood that the original ruling on inequitable conduct will be upheld, which will be a positive for Momenta. They found Dr. Uzan's testimony to be flawed and inconsistent, which they believe could impair his credibility and convince the Judge on intent to deceive. Firm expects a decision on this case sometime in the next 1-2 months.
The ongoing litigation increases firm's confidence in the favorable risk reward ratio for playing the Lovenox trial. Their analyses indicates a positive outcome from the trial could result in up to 50% upside (as the first major hurdle for generic Lovenox will be removed) whereas downside is relatively modest (10%-20%).
Reits Overweight on MNTA with a $30 tgt.
Notablecalls: Expect to see a positive reaction following the call. MNTA is a mover.
CONTRIBUTOR http://notablecalls.blogspot.com
Morgan Stanley is positive on Momenta Pharma (NASDAQ: MNTA) saying that after attending the ongoing '618 patent litigation, they believe there is a high likelihood that the original ruling on inequitable conduct will be upheld, which will be a positive for Momenta. They found Dr. Uzan's testimony to be flawed and inconsistent, which they believe could impair his credibility and convince the Judge on intent to deceive. Firm expects a decision on this case sometime in the next 1-2 months.
The ongoing litigation increases firm's confidence in the favorable risk reward ratio for playing the Lovenox trial. Their analyses indicates a positive outcome from the trial could result in up to 50% upside (as the first major hurdle for generic Lovenox will be removed) whereas downside is relatively modest (10%-20%).
Reits Overweight on MNTA with a $30 tgt.
Notablecalls: Expect to see a positive reaction following the call. MNTA is a mover.
CONTRIBUTOR http://notablecalls.blogspot.com
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
- DA Davidson Starts Everus (ECG) at Buy
Create E-mail Alert Related Categories
Analyst Comments, ContributorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
